文献
J-GLOBAL ID:201902252735775339
整理番号:19A0365851
進行肝細胞癌およびα-フェトプロテイン濃度増加(REACH-2)患者におけるソラフェニブ後のラムコリマブ:無作為化二重盲検プラセボ対照第3相試験【JST・京大機械翻訳】
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
著者 (28件):
Zhu Andrew X
(Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA, USA)
,
Kang Yoon-Koo
(Asan Medical Center, University of Ulsan, Seoul, South Korea)
,
Yen Chia-Jui
(Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital Tainan, Taiwan)
,
Yen Chia-Jui
(College of Medicine, National Cheng Kung University, Tainan, Taiwan)
,
Finn Richard S
(Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA)
,
Galle Peter R
(University Medical Center, Mainz, Germany)
,
Llovet Josep M
(Icahn School of Medicine at Mount Sinai, New York, NY, USA)
,
Llovet Josep M
(Institut d’Investigations Biomediques, August Pi i Sunyer-Hospital Clinic Barcelona, Barcelona, Spain)
,
Assenat Eric
(CHU de Montpellier, Montpellier, France)
,
Brandi Giovanni
(University Hospital S Orsola, Bologna, Italy)
,
Pracht Marc
(Centre Eugene Marquis, Rennes, France)
,
Lim Ho Yeong
(Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea)
,
Rau Kun-Ming
(Chang Gung Memorial Hospital-Kaohsiung Branch, Kaohsiung City, Taiwan)
,
Rau Kun-Ming
(Hematology-Oncology Department, E-Da Cancer Hospital, Kaohsiung, Taiwan)
,
Motomura Kenta
(Aso Iizuka Hospital-Hepatology, Iizuka, Fukuoka, Japan)
,
Ohno Izumi
(National Cancer Center Hospital East-Hepatobiliary and Pancreatic Oncology, Kashiwa, Chiba, Japan)
,
Merle Philippe
(Hopital de la Croix Rousse, Lyon, France)
,
Daniele Bruno
(Azienda Ospedaliera G Rummo, Benevento, Benevento, Italy)
,
Daniele Bruno
(Ospedale del Mare, Naples, Italy)
,
Shin Dong Bok
(Gachon University Gil Medical Center, Incheon, South Korea)
,
Gerken Guido
(Universtitaetsklinikum Essen AoR, Essen, North Rhine-Westphalia, Germany)
,
Borg Christophe
(University Hospital of Besancon, Besancon, France)
,
Hiriart Jean-Baptiste
(CHU de Bordeaux, Pessac, France)
,
Okusaka Takuji
(National Cancer Center Hospital, Tokyo, Japan)
,
Morimoto Manabu
(Kanagawa Cancer Center, Yokohama, Kanagawa, Japan)
,
Hsu Yanzhi
(Eli Lilly, New York, NY, USA)
,
Abada Paolo B
(Eli Lilly, Indianapolis, IN, USA)
,
Kudo Masatoshi
(Kindai University, Osaka-Sayama, Japan)
資料名:
Lancet Oncology
(Lancet Oncology)
巻:
20
号:
2
ページ:
282-296
発行年:
2019年
JST資料番号:
W1266A
ISSN:
1470-2045
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)